Search - tctmd.com

Displaying 21 - 30 of 30

Sort: Relevancy | Date

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

October 21, 2019

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

News Daily News

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

August 19, 2019

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

FDA Extends MitraClip Indication to Include Functional MR

News Daily News

FDA Extends MitraClip Indication to Include Functional MR

March 14, 2019

FDA Advisors Give Blessing to Implantable Pulse Generator in Certain Heart Failure Patients

News Daily News

FDA Advisors Give Blessing to Implantable Pulse Generator in Certain Heart Failure Patients

Yael L. Maxwell

December 05, 2018

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

November 01, 2018

Rapid Rule-Out Strategy with High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

News Daily News

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

April 17, 2017

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.